REG - Diaceutics PLC - Issue of Share Options / PDMR Shareholdings
01/04/2022 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220401:nRSA8615Ga&default-theme=true
RNS Number : 8615G Diaceutics PLC 01 April 2022
1 April 2022
Diaceutics PLC
("Diaceutics" or "the Company")
Issue of Share Options/PDMR Shareholdings
Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company,
announces the issue of 871,411 share options over ordinary shares of £0.002
each in the Company ("Share Options") to certain directors, members of the
Company's senior management team and other key staff, pursuant to the
Company's Employee Share Option Plan ("ESOP"). These awards are made in
accordance with the Company's long term incentive plan.
Share Options were granted as follows:
Name Number of Share Options granted Total no. of ordinary shares under option post grant % of existing issued share capital Effective Grant date
Peter Keeling, CEO 79,303 332,845 0.40% 1 April 2022
Nick Roberts, CFO 41,838 41,838 0.05% 1 April 2022
Ryan Keeling, CIO 72,290 316,444 0.38% 1 April 2022
Julie Browne, COO and PDMR 51,938 51,938 0.06% 1 April 2022
Jordan Clark, CCO and PDMR 50,495 50,495 0.06% 1 April 2022
Susanne Munksted, CPO and PDMR 50,953 174,075 0.21% 1 April 2022
Stefan McDonald, CGO and PDMR 48,463 81,722 0.10% 1 April 2022
Other employees (34 persons) 476,131 1,095,823 1.30% 1 April 2022
The Share Options vest on a sliding scale up to 100%, after three years from
the date of grant (the "Performance Period"), subject to the satisfaction of
certain performance criteria. The performance criteria is based upon the
growth in Total Shareholder Return, including any dividends declared and paid
during the Performance Period. The growth in TSR will be measured against a
base share price of 103.97p, being the average mid-market closing share price
in the three days prior to 31 March 2021. The exercise price of the Share
Options is £0.002 per share which equates to the nominal value of the shares.
Following this grant, the total number of share options outstanding in the
Company is 3,191,161, representing approximately 3.80% of its current issued
share capital of 84,063,923.
Enquiries:
Diaceutics PLC
Peter Keeling, Chief Executive Officer Via Alma PR
Nick Roberts, Chief Financial Officer
Stifel Nicolaus Europe Limited (Nomad & Broker) Tel: +44 (0)20 7710 7600
Ben Maddison, Stewart Wallace, Nick Adams
Alma PR Tel: +44(0)20 3405 0205
Caroline Forde, Kieran Breheny, Matthew Young diaceutics@almapr.co.uk
About Diaceutics
At Diaceutics we believe that every patient should have access to the right
treatment at the right time. We provide the world's leading pharmaceutical
companies with an end-to-end solution for the launch of precision medicine
diagnostics enabled by DXRX - The Diagnostic Network®.
DXRX is the world's first diagnostic commercialisation platform for precision
medicine, integrating multiple pipelines of real-world diagnostic testing data
from a global network of laboratories.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Peter Keeling
2 Reason for notification
a. Position/Status CEO, Director
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Options over new ordinary shares of 0.2p each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Grant of share options
c. Price(s) and volume(s)
Price(s) Volume(s)
Exercise price of 0.2p per share 79,303
e. Date of the transaction 1 April 2022
f. Place of the transaction Outside a trading venue
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Nick Roberts
2 Reason for notification
a. Position/Status CFO, Director
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Options over new ordinary shares of 0.2p each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Grant of share options
c. Price(s) and volume(s)
Price(s) Volume(s)
Exercise price of 0.2p per share 41,838
e. Date of the transaction 1 April 2022
f. Place of the transaction Outside a trading venue
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Ryan Keeling
2 Reason for notification
a. Position/Status CIO, Director
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Options over new ordinary shares of 0.2p each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Grant of share options
c. Price(s) and volume(s)
Price(s) Volume(s)
Exercise price of 0.2p per share 72,290
e. Date of the transaction 1 April 2022
f. Place of the transaction Outside a trading venue
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Julie Browne
2 Reason for notification
a. Position/Status COO and PDMR
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Options over new ordinary shares of 0.2p each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Grant of share options
c. Price(s) and volume(s)
Price(s) Volume(s)
Exercise price of 0.2p per share 51,938
e. Date of the transaction 1 April 2022
f. Place of the transaction Outside a trading venue
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Jordan Clark
2 Reason for notification
a. Position/Status CCO and PDMR
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Options over new ordinary shares of 0.2p each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Grant of share options
c. Price(s) and volume(s)
Price(s) Volume(s)
Exercise price of 0.2p per share 50,495
e. Date of the transaction 1 April 2022
f. Place of the transaction Outside a trading venue
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Susanne Munksted
2 Reason for notification
a. Position/Status CPO and PDMR
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Options over new ordinary shares of 0.2p each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Grant of share options
c. Price(s) and volume(s)
Price(s) Volume(s)
Exercise price of 0.2p per share 50,953
e. Date of the transaction 1 April 2022
f. Place of the transaction Outside a trading venue
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No.
596/2014
1 Details of the person discharging managerial responsibilities/person closely
associated
a. Name Stefan McDonald
2 Reason for notification
a. Position/Status CGO and PDMR
b. Initial notification/ Initial
Amendment
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a. Description of the financial instrument, type of instrument Options over new ordinary shares of 0.2p each
Identification Code
ISIN: GB00BJQTGV64
b. Nature of the transaction Grant of share options
c. Price(s) and volume(s)
Price(s) Volume(s)
Exercise price of 0.2p per share 48,463
e. Date of the transaction 1 April 2022
f. Place of the transaction Outside a trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END MSCGZGFFLMRGZZMRecent news on Diaceutics
See all newsREG - Diaceutics PLC - Notice of Results & Presentations
AnnouncementREG - Diaceutics PLC - PDMR Shareholding/SIP and TVR
AnnouncementREG - Diaceutics PLC - Appointment of Amie Mc Neice as VP of Marketing
AnnouncementREG - Diaceutics PLC - Block Listing Return
AnnouncementREG - Diaceutics PLC - PDMR Shareholding/Share Incentive Plan
Announcement